M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Ignyta submits RXDX-101's NDA to FDA, seeking approval in treating metastatic cancer patients
Biotechnology company Ignyta (OTC BB:RXDX) disclosed on Thursday the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for its proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, RXDX-101.
In conjunction with...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives